Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
We showed that members of the IGF-1/IGFBP-4/PAPP-A axis and FSTL-3 may serve as surrogate markers in breast cancer.
|
30388235 |
2019 |
Heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins.
|
30842316 |
2019 |
Congestive heart failure
|
0.030 |
Biomarker
|
disease |
BEFREE |
In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins.
|
30842316 |
2019 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We showed that members of the IGF-1/IGFBP-4/PAPP-A axis and FSTL-3 may serve as surrogate markers in breast cancer.
|
30388235 |
2019 |
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer.
|
28178680 |
2017 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer.
|
28178680 |
2017 |
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
Congestive heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown.
|
22915069 |
2012 |
Heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery.
|
18617621 |
2008 |
Congestive heart failure
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery.
|
18617621 |
2008 |
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Here, we show that activin-induced growth inhibition is altered in FLRG-expressing breast cancer lines.
|
17671190 |
2007 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Finally, a strong expression of FLRG was observed in invasive breast carcinomas in contrast with the normal luminal epithelial cells in which FLRG was not detected.
|
17671190 |
2007 |
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We compared circulating levels of: a) proglucagon-derived hormones (glucagon-like peptide [GLP]-1, GLP-2, glicentin, oxyntomodulin, glucagon, major proglucagon fragment [MPGF]), b) follistatins-activins (follistatin-like [FSTL]3, activin B), c) IGF axis (insulin-like growth factor [IGF]-1, total and intact IGF binding protein [IGFBP]-3 and IGFBP-4, and pregnancy associated plasma protein [PAPP]-A) in two studies: a) 18 individuals with early stage NAFLD vs. 14 controls (study 1; early NAFLD study) and in b) 31 individuals with biopsy proven NAFLD (15 with simple steatosis [SS] and 16 with nonalcoholic steatohepatitis [NASH]), vs. 50 controls (24 lean and 26 obese) (study 2).
|
31690932 |
2020 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the intensity of FSTL3 immunostaining correlated inversely with tumor size (r = -0.366, p<0.001) and with nuclear grade (p<0.01).
|
28178680 |
2017 |
Steatohepatitis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content.
|
23533219 |
2013 |
Fetal Growth Retardation
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Microarray experiments identified increased expression of certain genes including leptin, soluble vascular endothelial growth factor receptor, human chorionic gonadotropin, follistatin-like 3, and hypoxia-inducible factor 2alpha in the IUGR.
|
17240240 |
2007 |
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our data provide strong evidence that endogenous FLRG contributes to tumor cell proliferation through antagonizing endogenous activin effects.
|
17671190 |
2007 |
Fetal Growth Retardation
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Our results suggest that IGFBP1 and Follistatin-like 3 are highly up-regulated in IUGR in the placenta.
|
16338475 |
2006 |
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In more advanced stages, FSTL3 levels are higher in NASH compared to SS and, within NAFLD patients, in those with more severe lobular and portal inflammation.
|
31690932 |
2020 |
Tumor Cell Invasion
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
It was previously reported that follistatin-like 3(FSTL3), an activin A binding protein, contributes to the invasion and migration of trophoblast.
|
31810141 |
2020 |
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
Atherosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression.
|
31815869 |
2019 |
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We assessed the predictive value of GAL3 (galectin-3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease.
|
30929550 |
2019 |
Diabetes Mellitus, Non-Insulin-Dependent
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We investigated this hypothesis in humans by studying the physiology of a possible glycaemia-follistatin feedback loop, that is, whether glucose, but not lipid intake (oral or intravenous), can regulate circulating FST and FSTL3 in healthy humans (n = 32), whether the levels of follistatins change in response to various types of bariatric operation in morbidly obese individuals, with or without type 2 diabetes (n = 41), and whether such changes are associated prospectively with improvement of glucose homeostasis/insulin sensitivity.
|
30393997 |
2019 |
Cerebrovascular accident
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Framingham 10-year stroke risk (FSRP-10) quantified CVD-RFs.
|
30980900 |
2019 |